Brukinsa delivered powerful and sustained responses

Brukinsa delivers powerful and sustained responses

84% of patients responded to BRUKINSA across both studies1

Graph showing results of Study 206, PET-based, with 84% Overall Response Rate (24% partial response, 59% complete response) and Study 003, CT-based, with 84% Overall Response Rate (62% partial response, 22% complete response).

Median follow-up time was 18.4 months for Study 206 and 18.8 months for Study 0032

The efficacy of BRUKINSA was IRC-assessed in 2 clinical trials that included a total of 118 adult patients with MCL who received at least 1 prior therapy. Tumor response was according to the 2014 Lugano classification for both studies, and the primary efficacy endpoint was ORR as assessed by an IRC. Study BGB-3111-206 (Study 206): N=86, Phase 2, open-label, multicenter, single-arm trial; PET scans were required for response assessment. Study BGB-3111-AU-003 (Study 003): N=32, Phase 1/2, open-label, global, multicenter, single-arm trial; PET scans were not required for response assessment and the majority of patients were assessed by CT scan.

See Both Study Designs

Sustained results1

Most patients responded for more than 18 months

Graph showing results of Study 206, PET-based, with 19.5 months of Median Duration of Response, and Study 003, CT-based, with 18.5 months of Median Duration of Response.

Median follow-up time was 18.4 months for Study 206 and 18.8 months for Study 0032

CI=confidence interval; CR=complete response; CT=computed tomography; DOR=duration of response; IRC=independent review committee; NCCN=National Comprehensive Cancer Network; NE=not estimable; ORR=overall response rate; PET=positron emission tomography; PFS=progression-free survival; PR=partial response.

Zanubrutinib (BRUKINSA) is included as a second-line therapy option for 
MCL in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)3

Zanubrutinib is a preferred regimen for short response duration 
(< expected median PFS) and extended response duration 
(> expected median PFS) to prior chemoimmunotherapy

Flexible
Dosing

Dosing

Demonstrated
Safety Profile

Safety
myBeiGene

Personalized Patient
Support Program

Patient Support